BioCentury | Aug 18, 2020
Product Development

Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

...focus on  its preclinical ophthalmology and neurology programs.Next in line is UBX1325, a small molecule Bcl-XL...
...of diabetic retinopathy and hypoxia-induced retinopathy. Unpublished data show that in these models treatment with Bcl-xL...
BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

...interaction between BCL2L10 and a synthetic APOE4 that’s amenable to disruption by small molecules inhibiting BCL-XL...
...in animal models, but had no affect on the tumors in the presence of a BCL-XL...
BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

...Dialectic Therapeutics Inc. co-founders Guangrong Zheng and Daohong Zhou showed the company’s lead candidate, the anti-Bcl-XL...
...moiety of the Bcl-XL and BCL-2 dual inhibitor navitoclax linked to a vHL ligand, induced Bcl-XL...
...DT2216 inhibited tumor growth with only transient platelet count reductions, an adverse event associated with Bcl-XL...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

...CD3, it induces CD28 signaling, which prevents exhaustion by driving expression of the anti-apoptotic protein Bcl-XL...
BioCentury | Mar 27, 2019
Translation in Brief

A mitochondrial shield from cell death

...least 10 have cancer products approved or in development targeting the mitochondrial proteins BCL-2 and Bcl-XL...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...expansion and prevent differentiation of germinal cell B cells, by delivering the anti-apoptotic mitochondrial protein Bcl-XL...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Cancer

...culture and mouse studies suggest modulating SF3B1-mediated splicing alone or in combination with BCL-2 and Bcl-XL...
...compared with no treatment. Also in the cell lines, the SF3B1 modulator plus a dual BCL-2/Bcl-XL...
...vehicle. Next steps by H3 Biomedicine Inc. include investigating the therapeutic window for SF3B1-mediated splicing modulation/Bcl-XL...
BioCentury | Jan 18, 2019
Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

...monotherapies and in various combinations: HQP1351, a BCR-ABL inhibitor; APG-1252, a second generation BCL-2 and Bcl-XL...
...D824 NBTXR3, PEP503 Ascentage Pharma Group International Nanobiotix University of Texas MD Anderson Cancer Center B cell lymphoma 2 (BCL-2) (BCL2) Bcl-XL BCR-ABL...
BioCentury | Jan 7, 2019
Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

...iap inhibitor APG-2575 Ascentage Pharma Group International University of Texas MD Anderson Cancer Center B cell lymphoma 2 (BCL-2) (BCL2) Bcl-XL Inhibitor...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...model of the disease ( No. 2953 ). Dialectic Therapeutics Inc. presents data showing its Bcl-XL...
Items per page:
1 - 10 of 58